テネシーにおける食道癌の臨床試験
テネシー内の拠点で、食道癌に関する21件の研究が参加者を募集しています。
テネシー内の都市
公式研究テキスト（英語）
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2026/10/02更新 · NCT07283939A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07090499Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Sarah Cannon Research Institute- Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07519655Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Vanderbilt University Medical Center, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06047379Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Sarah Cannon - Tennessee Oncology, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Sarah Cannon Research Institute, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07431281A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- The University Of Tennessee Health Science Center, Memphis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/29更新 · NCT03526835A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- SCRI Oncology Partners, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/10更新 · NCT06695845A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- US Oncology Research LLC, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/06更新 · NCT04389632Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT06239194Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
- Veterans Affairs Medical Center - Nashville, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/05更新 · NCT00899626cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
被験者募集中観察研究健康なボランティア歓迎
40歳以上 · 全性別 · 2026/01/20更新 · NCT05366881A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/01/12更新 · NCT07181473SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。